Review Article
Targeted Therapy in Hepatocellular Carcinoma
| Agent | Study | Phase | Comparator arm | No. of patients | Response rate | TTP (median months) | OS (median months) | AEs |
| Sorafenib | Abou-Alfa et al. [35] | II | — | 137 | 34% SD 8% PR/MR | — | 9.2 | HFS, diarrhea, fatigue |
| | SHARP trial Llovet et al. [38] | III | Vs placebo | 602 | 2% PR No CR | 5.5 versus 2.8 | 10.7 versus 7.9 | HFS (21%), diarrhea (39%) |
| | Cheng et al. [39] | III | Vs placebo | 271 | — | 2.8 versus 1.4 | 6.5 versus 4.2 | HFS (45%), diarrhea (26%), rash (20%), fatigue (20%) |
| Sorafenib + TACE | START trial Chung et al. [41] | II | — | 50 (evaluable) | 36% CR 60% PR/SD | — | — | — |
| Sorafenib + doxorubicin | Abou-Alfa et al. [42] | II | Vs doxorubicin | 96 | — | 6.4 versus 2.8 | 13.7 versus 6.5 | Same both arms |
| Bevacizumab | Siegel et al. [43] | II | — | 46 | 13% PR | | 53% (1 yr) 28% (2 yr) 23% (3 yr) | Hypertens ion (15%), thrombos is (6%) |
| Bevacizumab + gemcitabine + oxaliplatin | Zhu et al. [44] | II | — | 30 (evaluable) | 20% RR 27% SD | — | 9.6 | — |
| Bevacizumab + capecitabine + oxaliplatin | Sun et al. [45] | II | — | 30 (evaluable) | 13% PR 77% SD | 4.5 | 10.3 | — |
| Bevacizumab + capecitabine | Hsu et al. [46] | II | — | 45 | 9% RR 52% CR/PR/SD | 2.7 (PFS) | 5.9 | HFS 9% BGIT 9% |
| Bevacizumab + erlotinib | Thomas et al. [47] | II | — | 40 | — | 9 (PFS) | 15.6 | BGIT 13%, fatigue 20%, hypertens ion 15% |
| Sunitinib | Zhu et al. [48] | II | — | 34 | 50% SD | 4.1 | — | — |
| | Faivre et al. [49] | II | — | 37 | 2% PR 35% SD | 3.7 (PFS) | 8 | Significant 4 deaths, trial stopped |
| ABT-69 | Toh et al. [50] | II | — | 44 (34 evaluable) | 8.7% (23 CP A pts) | 3.7 | 9.8 | Mostly mild mod |
| Erlotinib | Philip et al. [51] | II | — | 38 | 9% PR | 32% (6 months PFS) | 13 | — |
| | Thomas et al. [52] | II | — | 40 | — | 28% (6 months PFS) | 3.3 | — |
|
|
RR: overall response rate, MR: minor response, PR: partial response, SD: stable disease, CR: complete response, PFS: progression-free survival, TTP: time to progression, OS: overall survival, AEs: adverse events, HFS: hand-foot syndrome, BGIT: bleeding gastrointestinal tract, CP A: Child Pugh A.
|